Nozawa, K., Ozaki, Y., Oshino, T., Terata, K., Funasaka, C., Sakai, H., Futamura, M., Kitagawa, C., Iwasa, T., Toyama, T., Ishihara, M., Kashiwagi, S., Matsumoto, K., Takahashi, Y., Watanabe, S., Shigematsu, H., Takano, T. (2026). A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps1163